Difference between revisions of "Lurasidone-Fluphenazine LA"
From Psychiatrienet
(Created page with '{{Drugswitch | from = Lurasidone | to = Fluphenazine_LA | stop = {{Downslweeks}} | start = {{StartDepot}} | info = {{caveQT}}{{Alternatief}} | view = Stop10WeeksStartDepot.jpg') |
|||
| Line 6: | Line 6: | ||
| info = {{caveQT}}{{Alternatief}} | | info = {{caveQT}}{{Alternatief}} | ||
| view = Stop10WeeksStartDepot.jpg | | view = Stop10WeeksStartDepot.jpg | ||
| + | } | ||
Revision as of 09:21, 16 March 2015
{{Drugswitch | from = Lurasidone | to = Fluphenazine_LA | stop =
- Week 1-3: approx. 75% of initial dose
- Week 4-6: approx. 50% of initial dose
- Week 7-9: approx. 25% of initial dose
- Week 10: stop
| start =
- Day 1: Start depot according general dosing advice (Dotted line in graph)
| info =
- During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
- There is a possibility of QT interval prolongation.[1]
- Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.
| view = Stop10WeeksStartDepot.jpg
}
- ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
